Year: 2017

Purchase #9: Oliver’s Real Food Ltd

I recently made the 9th purchase for the portfolio, Oliver’s Real Food Ltd (ASX: OLI). As with the Just Group purchase, I think the shorter thesis length is a winner and I will stick to that format here. Oliver’s has ~210m shares on issue including 2.7 million options. It has a market capitalisation of ~$46 million …

Quarterly review September: Q1 2018

So ends the second quarter of 10foot’s short life so far. On balance, I should have underperformed, given that I blew 4% of my capital on RNY Property Trust and lost a little bit on Thorn Group Ltd (ASX: TGA), plus I pay 3% in transaction fees, so I am behind from the get-go. The 10foot portfolio was …

Strong narratives: A source of competitive advantage?

One of the best things about investing is that you will draw on virtually all of your skills, knowledge, and experience at one point or another. I studied narratives at school, formally, as an academic pursuit. It sounds dry, and it kinda was, but it’s proven to be valuable in highly unusual ways. Try deconstructing a …

On Catalonia

The general view on Twitter and in the media seems to be that ‘Spain is grossly overreacting to the illegal Catalan referendum.’ Fair point. It is not a pretty picture. However, if we ask why Spain is overreacting, a different picture emerges: Autonomy Although a parliamentary monarchy, Spain is a decentralized nation composed of autonomous regions and cities. …

What is a synthetic subprime CDO?

Six months ago I was asked to explain what a synthetic CDO was.  Well pal, the sky is blue because bankers in Wall Street…. I sort of did my best and drew a few diagrams and we got about halfway there and came to a halt. I understand roughly how a synthetic CDO works, I …

Q1 2018: 10foot is up 70% FYTD

As we prepare our upcoming quarterly review, we are pleased to announce that the 10foot portfolio has returned approximately 70% since last quarter and now has an unaudited total net asset value (NAV) of $16,830 versus an initial value of $10,000 at inception. There has also been a change in the structure of the fund, …

Through a Mayne Pharma, Concisely

I put 5% of the 10foot portfolio in Mayne Pharma (ASX: MYX). My purchase thesis was way too long to be useful to readers. I have created an abbreviated version here: Mayne is undervalued given its cash earning ability Performance in FY18 will provide a much clearer picture of the combined organisation’s (post Teva/Allergan portfolio acquisition) …

Purchase #7: Mayne Pharma Group Ltd

I’ve made another purchase for the 10foot portfolio, generic pharmaceutical company Mayne Pharma Group Ltd (ASX: MYX). Mayne manufactures and sells generics, consults for third parties,  sells its own specialty branded drugs, and develops new formulations for existing molecules. Mayne Pharma recently had a huge step-change in its operations after the $900m acquisition of a portfolio …

The things that move share prices

I have recently been reading through well-known investing blogs like Bronte Capital (John Hempton) and Bristlemouth (Forager/Steve Johnson) from their beginnings in 2008 or so. They are very good. I read Hempton’s in its entirety a few years ago and I would recommend his earlier posts as an excellent crash course in how the truck …

The Gig Economy

Despite being financially comfortable and gainfully employed myself, one of the things I find myself becoming increasingly opposed to is the growing ‘gig-ification’ of work and/or what I see as the increasing abuse of workers (which are sometimes the same thing and sometimes two separate issues). So much has been said about this in the …